Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus

Science

Volumn 342, Issue 6158, 2013, Pages 592-598

  McLellan, Jason S ^a   Chen, Man ^a   Joyce, M Gordon ^a   Sastry, Mallika ^a   Stewart Jones, Guillaume B E ^a   Yang, Yongping ^a   Zhang, Baoshan ^a   Chen, Lei ^a   Srivatsan, Sanjay ^a   Zheng, Anqi ^a   Zhou, Tongqing ^a   Graepel, Kevin W ^a   Kumar, Azad ^a   Moin, Syed ^a   Boyington, Jeffrey C ^a   Chuang, Gwo Yu ^a   Soto, Cinque ^a   Baxa, Ulrich ^b   Bakker, Arjen Q ^c   Spits, Hergen ^c   Beaumont, Tim ^c   Zheng, Zizheng ^d   Xia, Ningshao ^d   Ko, Sung Youl ^a   Todd, John Paul ^a   Rao, Srinivas ^a   Graham, Barney S ^a   Kwong, Peter D ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; MOTAVIZUMAB; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS FUSION PROTEIN;

ANTIBODY; CRYSTAL STRUCTURE; DESIGN; HOSPITAL SECTOR; IMMUNIZATION; NEUTRALIZATION; OSMOSIS; PH; PROTEIN; STABILIZATION; THRESHOLD; VIRUS;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; GENETIC VARIABILITY; HUMORAL IMMUNITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; OSMOLALITY; PH; PRIORITY JOURNAL; PROTEIN STRUCTURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

MACACA; MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84887277978     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1243283     Document Type: Article

References (49)

1. R. Lozano et al., Lancet 380, 2095-2128 (2012).
2. S. Johnson et al., J. Infect. Dis. 176, 1215-1224 (1997).
3. The IMpact-RSV Study Group, Pediatrics 102, 531-537 (1998).
4. L. J. Earp, S. E. Delos, H. E. Park, J. M. White, Curr. Top. Microbiol. Immunol. 285, 25-66 (2005).
5. J. S. McLellan, Y. Yang, B. S. Graham, P. D. Kwong, J. Virol. 85, 7788-7796 (2011).
6. K. A. Swanson et al., Proc. Natl. Acad. Sci. U.S.A. 108, 9619-9624 (2011).
7. J. S. McLellan et al., Science 340, 1113-1117 (2013).
8. L. Liljeroos, M. A. Krzyzaniak, A. Helenius, S. J. Butcher, Proc. Natl. Acad. Sci. U.S.A. 110, 11133-11138 (2013).
9. L. J. Anderson et al., Vaccine 31 (suppl. 2), B209-B215 (2013).
10. M. Magro et al., Proc. Natl. Acad. Sci. U.S.A. 109, 3089-3094 (2012).
11. H. Spits, T. Beaumont, RSV-specific binding molecules and means for producing them. Patent Application 12/600,950 (2010).
12. T. Beaumont, A. Q. Bakker, E. Yasuda, RSV specific binding molecule. Patent Application 12/898,325 (2012).
13. D. R. Burton, Nat. Rev. Immunol. 2, 706-713 (2002).
14. T. Zhou et al., Nature 445, 732-737 (2007).
15. G. Ofek et al., Proc. Natl. Acad. Sci. U.S.A. 107, 17880-17887 (2010).
16. J. Jardine et al., Science 340, 711-716 (2013).
17. A. T. McGuire et al., J. Exp. Med. 210, 655-663 (2013).
18. J. S. McLellan et al., Nat. Struct. Mol. Biol. 17, 248-250 (2010).
19. J. S. McLellan et al., J. Mol. Biol. 409, 853-866 (2011).
20. L. Kong et al., Nat. Struct. Mol. Biol. 20, 796-803 (2013).
21. V. P. Efimov et al., J. Mol. Biol. 242, 470-486 (1994).
22. K. A. Miroshnikov et al., Protein Eng. 11, 329-332 (1998).
23. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
24. Information on materials and methods is available on Science Online.
25. RSV F variants were assessed by transient expression in 96-well format (fig. S4). If supernatants retained reactivity with antibodies motavizumab and D25 after 1 week at 4°C, they were expressed by transient transfection of 1 liter of Expi293F cells, purified by use of appended His-tag and StreptagII, and analyzed by size-exclusion chromatography (fig. S7).
26. The inability to express potential interchain double-cysteine substitutions, despite reasonable modeling in the mature prefusion F1F2 structure, may indicate that RSV F0 protomers, before cleavage and removal of peptide 27, adopt substantially different interprotomer conformations.
27. Cavities in the D25-bound RSV F structure were visualized with PyMol using the "Cavities & Pockets Only" option for Surface settings. Amino acid substitutions designed to fill the resulting cavities were identified using the Mutagenesis wizard.
28. M. Pancera et al., PLOS ONE 8, e55701 (2013).
29. The engineered RSV F variants had Ca-root mean square deviations from the D25-bound conformation of 0.7 to 1.5 Å and from the postfusion conformation of approximately 30 Å.
30. Crystallized DS retained ∼20% of its D25 recognition relative to crystallized Cav1 (normalized to motavizumab recognition) after 4 months at 20°C, thereby indicating that the crystallized DS was both capable of recognizing D25 as well as converting to a conformation incompatible with D25 binding. By contrast, soluble DS lost all recognition of D25 after 2 months of incubation at 4°C in PBS. We were unable to crystallize DS, which had been heat triggered at 50°C, despite the heat-triggered DS retaining a trimeric state on size exclusion chromatography.
31. Observing Ala107 rather than Arg109 at the C terminus of F2 is not totally unexpected: Garten and Klenk (48) found that an arginine at the cleavage site of influenza hemagglutinin was trimmed by a cellular carboxypeptidase activity.
32. Ca-root mean square deviations of 0.86 Å for 447 residues between Cav1 and DS-Cav1 crystal structures obtained from ammonium sulfate; Ca-root mean square deviations of 0.47 Å for 447 residues of DS-Cav1 in cubic lattices.
33. J. Stetefeld et al., Structure 11, 339-346 (2003).
34. When palivizumab (Synagis) is dosed at a concentration of 15 mg/kg, serum levels at trough are ∼40 mg/ml, which provides protection in infants from severe disease and protection in cotton rats from RSV infection. In our neutralization assay, ∼40 mg/ml of palivizumab yields an EC50 of 100.
35. G. J. Nabel, Science 326, 53-54 (2009).
36. By contrast, affinity of RSV F variants for D25 antibody did not show correlation with elicitation of protective titers. Yield of RSV F trimers also did not correlate with protective titers.
37. Flexibility of an antigenic site may increase its immunogenicity by allowing the site to conform to a wider diversity of antibodies. We note in this context that the atomic-mobility factors of antigenic site Ø were among the highest in the RSV F ectodomain.
38. For the "prefusion" form of RSV F, we used the DS-Cav1 stabilized variant of RSV F.
39. It should be possible to deconvolute the elicited response, by using structurally defined probes, as shown with D25 and motavizumab-bound RSV F in fig. S12.
40. P. R. Dormitzer, G. Grandi, R. Rappuoli, Nat. Rev. Microbiol. 10, 807-813 (2012).
41. M. L. Azoitei et al., Science 334, 373-376 (2011).
42. I. Delany, R. Rappuoli, K. L. Seib, Cold Spring Harb. Perspect. Med. 3, a012476 (2013).
43. A. Sette, R. Rappuoli, Immunity 33, 530-541 (2010).
44. D. G. Moriel et al., Proc. Natl. Acad. Sci. U.S.A. 107, 9072-9077 (2010).
45. M. Mora, C. Donati, D. Medini, A. Covacci, R. Rappuoli, Curr. Opin. Microbiol. 9, 532-536 (2006).
46. Although an epitope-scaffold strategy may not elicit titers as high as a neutralization-sensitive site strategy, for specific antibodies - such as antibody MPE8 (49), which is capable of neutralizing not only RSV but other paramyxoviruses including human metapneumovirus - an epitope-specific strategy may suffice.
47. The magnitude of antibody activity is a crucial determinant of how well an individual will be protected following vaccination and how long protective responses will be maintained in infants who have passively acquired antibody from their mothers.
48. W. Garten, H. D. Klenk, J. Gen. Virol. 64, 2127-2137 (1983).
49. D. Corti et al., Nature 501, 439-443 (2013).